The Estée Lauder Companies signed a joint development agreement with biotech firm Atropos Therapeutics.
WHO: Founded in 2018, Atropos is a biotech platform company focused on the discovery, development, and commercialization of therapies targeting the formation of senescent cells. The company says it “leverages unexploited insights in senescence biology to discover agents and modalities.” This disruptive approach to aging disorders targets that which is common to these diseases—the stress-induced accumulation of the senescent cell in various tissues.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skincare, makeup, fragrance, and haircare products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, Tory Burch, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, and Too Faced.
WHY: The focus of the agreement is to explore the botanical space for molecules that modulate senescence.
IN THEIR OWN WORDS: “Atropos’ in-depth understanding of and its unique and well-validated approaches to identify senescence modulators will synergize well with our expertise in the natural product space. Botanically derived senosuppressors are not only sure to be interesting new molecules—the utilization of such will have great commercial potential for us,” said Tom Mammone, VP of Skin Physiology and Pharmacology at The Estée Lauder Companies.
“Partnering with The Estée Lauder Companies, a leader in global prestige beauty that uses natural products nicely complements our pipeline efforts to identify senomodulating chemicals by high content screening and using AI based drug design to interfere with activities necessary for geroconversion and senescence. With the three pipelines open, Atropos can move to the next stage of its development with isolated molecules in hand,” said Andrew Koff, founder of Atropos Therapeutics.
DETAILS:
